N Wilcken
Overview
Explore the profile of N Wilcken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
524
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cameron B, Webber K, Li H, Bennett B, Boyle F, de Souza P, et al.
Brain Behav Immun Health
. 2021 Sep;
10:100189.
PMID: 34589724
Background: Cancer-related fatigue, mood disturbances, pain and cognitive disturbance are common after adjuvant cancer therapy, but vary considerably between individuals despite common disease features and treatment exposures. A genetic basis...
2.
Vasista A, Stockler M, West T, Wilcken N, Kiely B
Breast
. 2016 Nov;
31:99-104.
PMID: 27829202
Objectives: To estimate worst-case, typical and best-case scenarios for survival as a communication aid for managing patients with HER2-positive metastatic breast cancer (MBC) starting HER2-targeted therapies. Methods: We sought randomised...
3.
Schofield P, Stockler M, Zannino D, Tebbutt N, Price T, Simes R, et al.
Support Care Cancer
. 2015 Jun;
24(1):401-408.
PMID: 26093975
Purpose: Psychological responses to cancer are widely believed to affect survival. We investigated associations between hope, optimism, anxiety, depression, health utility and survival in patients starting first-line chemotherapy for metastatic...
4.
Gupta S, Taylor N, Selvakumar D, Harnett P, Wilcken N, Lee C
Intern Med J
. 2014 Aug;
44(12a):1235-9.
PMID: 25169081
Background: Cancer patients often require complex and expensive admissions necessitating multiple investigations. We conducted an audit of cost of imaging performed on medical oncology inpatients in a teaching hospital in...
5.
McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, et al.
Breast
. 2014 Jan;
23(2):142-51.
PMID: 24393617
Background: Neoadjuvant chemotherapy has a sound rationale for use in women with large operable breast cancer, and achievement of pathological complete response (pCR) is prognostic. Epirubicin and cyclophosphamide followed by...
6.
Cameron B, Bennett B, Li H, Boyle F, deSouza P, Wilcken N, et al.
Ann Oncol
. 2012 Jun;
23(11):2890-2895.
PMID: 22674147
Background: Prolonged fatigue after cancer treatment is common. The pathophysiology of such post-cancer fatigue (PCF) is unknown, although cross-sectional studies suggest increased pro-inflammatory cytokine production. This study investigated the association...
7.
Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Heinemann V, et al.
Ann Oncol
. 2009 Jul;
20(11):1771-85.
PMID: 19608616
Background: Treatment options for patients with metastatic breast cancer (MBC) include a rapidly expanding repertoire of medical, surgical and supportive care measures. Design: To provide timely and evidence-based recommendations for...
8.
Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak A
Cochrane Database Syst Rev
. 2007 Oct;
(4):CD004421.
PMID: 17943815
Background: Adjuvant chemotherapy improves survival in pre- and post-menopausal women with early breast cancer. Taxanes are highly active chemotherapy agents in metastatic breast cancer. Their role in early breast cancer...
9.
Gurney H, Wong M, Balleine R, Rivory L, McLachlan A, Hoskins J, et al.
Clin Pharmacol Ther
. 2007 May;
82(1):33-40.
PMID: 17495881
The aim of this study was to explore the impact of individual variation in drug elimination on imatinib disposition. Twenty-two patients with gastrointestinal stromal tumor or chronic myeloid leukemia initially...
10.
Jones D, Ghersi D, Wilcken N
Cochrane Database Syst Rev
. 2006 Jul;
(3):CD003368.
PMID: 16856005
Background: The addition of a chemotherapy drug or drugs to an established regimen is one method used to increase the dose and intensity of treatment for metastatic breast cancer. Objectives:...